CC BY-NC-ND 4.0 · Endosc Int Open 2023; 11(01): E97-E104
DOI: 10.1055/a-1997-9149
Innovation forum

Usefulness of a laser-cut covered metal stent with a 7F delivery sheath in endoscopic ultrasound-guided biliary drainage without fistula dilation

Kotaro Takeshita
1   Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Japan, Tokyo, Japan
,
1   Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Japan, Tokyo, Japan
,
Yoshikuni Nagashio
1   Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Japan, Tokyo, Japan
,
Yuta Maruki
1   Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Japan, Tokyo, Japan
,
Akihiro Ohba
1   Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Japan, Tokyo, Japan
,
Yuki Kawasaki
1   Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Japan, Tokyo, Japan
,
Yuya Hisada
1   Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Japan, Tokyo, Japan
,
1   Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Japan, Tokyo, Japan
,
Shota Harai
1   Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Japan, Tokyo, Japan
,
Hidetoshi Kitamura
1   Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Japan, Tokyo, Japan
,
Takehiko Koga
1   Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Japan, Tokyo, Japan
,
Kosuke Maehara
1   Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Japan, Tokyo, Japan
,
Yumi Murashima
1   Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Japan, Tokyo, Japan
,
Natsumi Yamada
1   Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Japan, Tokyo, Japan
,
Mao Okada
1   Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Japan, Tokyo, Japan
,
Tetsuro Takasaki
1   Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Japan, Tokyo, Japan
,
Daiki Agarie
1   Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Japan, Tokyo, Japan
,
Hidenobu Hara
1   Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Japan, Tokyo, Japan
,
Yuya Hagiwara
1   Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Japan, Tokyo, Japan
,
Kohei Okamoto
1   Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Japan, Tokyo, Japan
,
Daiki Yamashige
1   Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Japan, Tokyo, Japan
,
Shunsuke Kondo
1   Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Japan, Tokyo, Japan
,
Chigusa Morizane
1   Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Japan, Tokyo, Japan
,
Hideki Ueno
1   Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Japan, Tokyo, Japan
,
Yutaka Saito
2   Endoscopy Division, National Cancer Center Japan, Tokyo, Japan
,
Takuji Okusaka
1   Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Japan, Tokyo, Japan
› Author Affiliations
Supported by: The National Cancer Center Research and Development Fund 2022-A-16

Abstract

Background and study aims Recently, the utility of endoscopic ultrasound-guided intervention without fistula dilation (EUS-IV WoD) has been reported to prevent adverse events. We clinically evaluated cases in which EUS-IV WoD was attempted using a novel self-expandable metallic stent (SEMS); this is a fully covered, laser-cut SEMS that has a tapered and stiff tip specifically designed for a 0.025-inch guidewire and a relatively thin, 7F delivery system.

Patients and methods We retrospectively evaluated cases wherein EUS-IV WoD was attempted using the novel SEMS between March and December 2021.

Results Treatment of 11 patients by EUS-IV WoD with the novel SEMS was attempted. The technical success rate for EUS-IV was 100 % and the clinical success rate was 100 %; the success rate for EUS-IV WoD was 72.8 %. Of these, the procedural success rate for EUS-IV WoD was 100 % in EUS-biliary drainage (BD) and 57.1 % in non-EUS-BD. Early adverse events were observed in 27.3 % of patients (3/11): mild abdominal pain in two patients and moderate bleeding in one patient. The abdominal pain cases were both cases of EUS-IV WoD failure and required fistula dilation.

Conclusions The novel stent may be useful for EUS-IV WoD, especially in EUS-BD.



Publication History

Received: 16 October 2022

Accepted after revision: 08 December 2022

Article published online:
26 January 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Moss AC, Morris E, Leyden J. et al. Do the benefits of metal stents justify the costs? A systematic review and meta-analysis of trials comparing endoscopic stents for malignant biliary obstruction. Eur J Gastroenterol Hepatol 2007; 19: 1119-1124
  • 2 Dhindsa BS, Mashiana HS, Dhaliwal A. et al. EUS-guided biliary drainage: a systematic review and meta-analysis. Endosc Ultrasound 2020; 9: 101-109
  • 3 Park DH, Lee TH, Paik WH. et al. Feasibility and safety of a novel dedicated device for one-step EUS-guided biliary drainage: a randomized trial. J Gastroenterol Hepatol 2015; 30: 1461-1466
  • 4 Itonaga M, Kitano M, Hatamaru K. et al. Endoscopic ultrasound-guided choledochoduodenostomy using a thin stent delivery system in patients with unresectable malignant distal biliary obstruction: a prospective multicenter study. Dig Endosc 2019; 31: 291-298
  • 5 Maehara K, Hijioka S, Nagashio Y. et al. Endoscopic ultrasound-guided hepaticogastrostomy or hepaticojejunostomy without dilation using a stent with a thinner delivery system. Endosc Int Open 2020; 8: E1034-E1038
  • 6 Koga T, Hijioka S, Nagashio Y. et al. Endoscopic ultrasound‐guided choledochoduodenostomy without fistula dilation using a stent with a 5.9‐Fr delivery system: comparison to a conventional procedure with fistula dilation. DEN Open 2021; 2: e56
  • 7 Ogura T, Ueno S, Okuda A. et al. Technical feasibility and safety of one-step deployment of EUS-guided hepaticogastrostomy using an 8-mm diameter metal stent with a fine-gauge stent delivery system (with video). Endosc Ultrasound 2021; 10: 355-360
  • 8 Isayama H, Hamada T, Yasuda I. et al. TOKYO criteria 2014 for transpapillary biliary stenting. Dig Endosc 2015; 27: 259-264
  • 9 Cotton PB, Eisen GM, Aabakken L. et al. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc 2010; 71: 446-454
  • 10 Harai S, Hijioka S, Nagashio Y. et al. Usefulness of the laser-cut, fully covered, self-expandable metallic stent for endoscopic ultrasound-guided hepaticogastrostomy. J Hepatobiliary Pancreat Sci 2022; 29: 1035-1043